Clinical Trials Logo

Advanced Tumor clinical trials

View clinical trials related to Advanced Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05839106 Recruiting - Advanced Tumor Clinical Trials

Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors

Start date: July 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose(RP2D) of PM1032.

NCT ID: NCT05607563 Recruiting - Advanced Tumor Clinical Trials

A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

Start date: November 21, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose(RP2D) of PM1009. PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.

NCT ID: NCT05108779 Recruiting - Advanced Tumor Clinical Trials

QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors

Start date: November 9, 2021
Phase: Phase 1
Study type: Interventional

To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies.